Articles

CG Life's Strategic C-Suite Expansion: Insights and Implications

CG Life has appointed Collette Douaihy as Chief Creative Officer, marking a significant step in its C-suite expansion. This article explores the implications for the pharmaceutical sector.

Bristol Myers' $1B Manufacturing Plant Plans in Houston

Bristol Myers is considering a significant investment in a $1B manufacturing plant in Houston, which could reshape its operational landscape. This article delves into the implications for the pharmaceutical sector.

Relay's PI3Kα Inhibitor Shows Promise in Phase 2 Study

Relay's PI3Kα inhibitor has demonstrated significant efficacy in a Phase 2 study targeting vascular anomalies, raising investment interest.

Roche Expands Alecensa Approval in Japan: Implications for Pharma

Roche has received approval to expand Alecensa's use in Japan for all ALK tumor types. This article explores the implications for pharma stakeholders.

Future Uses for CGM: Insights from Dexcom's CEO

Dexcom's CEO hints at innovative future uses for continuous glucose monitoring (CGM) technology. This article explores the implications for the pharmaceutical sector.

Virginia Governor Vetoes Drug Cost Advisory Panel Legislation

Virginia's governor has vetoed a bill aimed at creating a panel to lower prescription drug costs, raising questions about future drug pricing strategies.

Regulatory Education for 2026: What to Expect

The Regulatory Education event in 2026 promises to be a pivotal gathering for industry leaders. Stay informed on key takeaways and what to watch for.

AI Revolutionizes Treatment for Newborn's Ultra Rare Disease

This article explores the transformative role of AI in treating a newborn's ultra rare disease, highlighting its implications for the pharmaceutical industry.

Trump's Cuts to Foreign Aid: Implications for Ebola Response

This article examines the implications of Trump's foreign aid cuts on the Ebola response, highlighting key insights for pharmaceutical stakeholders.

Understanding the Cost Disparities in Spine Surgery Under the No Surprises Act

This article examines the stark contrast in spine surgery costs due to the No Surprises Act, highlighting implications for pharmaceutical stakeholders.

AI Revolutionizes Treatment for Ultra Rare Disease in Newborns

This article explores the transformative role of AI in treating an ultra rare disease in a newborn, highlighting its implications for the pharmaceutical industry.

ISPOR 2026: Key Insights and What to Expect

ISPOR 2026 promises to be a pivotal event for B2B stakeholders in the pharma industry. Here's what to expect and who to watch.

Senate Democrats Propose Long-Term Care Benefit for Medicare

Senate Democrats have proposed a new long-term care benefit for Medicare, potentially reshaping the landscape of healthcare funding. This article explores the implications for pharmaceutical companies and investors.

Supreme Court's IRA Decision: Implications for Pharma Deals

The Supreme Court's refusal to hear IRA challenges from Novo and AstraZeneca has significant implications for the pharmaceutical industry. This article explores the potential impacts on business development and investment strategies.

Impact of Trump's Foreign Aid Cuts on Ebola Response

This article examines the implications of Trump's foreign aid cuts on the Ebola response, highlighting key insights for pharmaceutical stakeholders.

SCOPE X 2026: Key Insights and Coverage

SCOPE X 2026 is set to be a pivotal event for B2B readers in the pharma sector. This article covers key insights, company watchlists, and essential data readouts.

Navigating the Data: Pre-Event Coverage for 2026

As the Navigating the Data event approaches, B2B readers can prepare by understanding key insights and companies to watch. This pre-event coverage highlights essential takeaways and FAQs.

The Rise of Perimenopause Misinformation: Implications for Pharma

This article examines the growing misinformation surrounding perimenopause and its potential impact on pharmaceutical strategies. Understanding these dynamics is crucial for industry stakeholders.

Impact of 600 Generic Meds Added to TrumpRx Portal

The White House has expanded the TrumpRx purchasing portal by adding 600 generic medications. This article explores the implications for the pharmaceutical industry.

Virginia Governor Vetoes Legislation on Prescription Drug Costs

The Virginia governor has vetoed a bill aimed at creating a panel to lower prescription drug costs. This decision raises questions about future drug pricing strategies in the state.